3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Diseases
1
Primary Myelofibrosis
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Polycythemia Vera
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Interventions
darolutamide
3
enzalutamide
2
Pluvicto
2
talazoparib
1
olaparib
1
gedatolisib
1
apalutamide
1
Standard of Care
1
Radiotherapy
1
Prednisone
1
Lutetium-177
1
Lutetium
1
Docetaxel
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Diseases
×
talazoparib
×
Clear all
NCT06582628
2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2
Recruiting
78 enrolled